Cargando…
Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokin...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712954/ https://www.ncbi.nlm.nih.gov/pubmed/32998224 http://dx.doi.org/10.3390/jof6040192 |
_version_ | 1783618484137099264 |
---|---|
author | Zhao, Yanan Perlin, David S. |
author_facet | Zhao, Yanan Perlin, David S. |
author_sort | Zhao, Yanan |
collection | PubMed |
description | Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokinetics, as well as an administration advantage in the clinical setting compared to other drugs in the same class. Rezafungin displays potent in vitro activity against a wide spectrum of fungal pathogens, which is reflected in robust in vivo efficacy and/or pharmacodynamic studies using various animal models as well as in promising clinical trials data. This review describes in vivo characterization of rezafungin using animal models, current status of clinical development and key findings from these studies. |
format | Online Article Text |
id | pubmed-7712954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77129542020-12-04 Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data Zhao, Yanan Perlin, David S. J Fungi (Basel) Review Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokinetics, as well as an administration advantage in the clinical setting compared to other drugs in the same class. Rezafungin displays potent in vitro activity against a wide spectrum of fungal pathogens, which is reflected in robust in vivo efficacy and/or pharmacodynamic studies using various animal models as well as in promising clinical trials data. This review describes in vivo characterization of rezafungin using animal models, current status of clinical development and key findings from these studies. MDPI 2020-09-28 /pmc/articles/PMC7712954/ /pubmed/32998224 http://dx.doi.org/10.3390/jof6040192 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhao, Yanan Perlin, David S. Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data |
title | Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data |
title_full | Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data |
title_fullStr | Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data |
title_full_unstemmed | Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data |
title_short | Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data |
title_sort | review of the novel echinocandin antifungal rezafungin: animal studies and clinical data |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712954/ https://www.ncbi.nlm.nih.gov/pubmed/32998224 http://dx.doi.org/10.3390/jof6040192 |
work_keys_str_mv | AT zhaoyanan reviewofthenovelechinocandinantifungalrezafunginanimalstudiesandclinicaldata AT perlindavids reviewofthenovelechinocandinantifungalrezafunginanimalstudiesandclinicaldata |